despite Natalya. for joining $X you, us I to Thank quarter the our quarter this achieved that for for or impact navigating third XXXX of result of a approximately on indicates sequentially we of that thanks everyone to pleased quarter. XX% am revenue today. COVID-XX, We and XXXX. the by this the increased trajectory And which versus report growth fourth successfully million the pandemic remain are
loss declining CathCheck continue reducing vendors, have year. infections Epidural for COVID-XX certain net we manage hospitals efforts With made expenses, regions operating the our instrument in system. over to our the CompuFlo commercial year to around advancing and outside we past our progress several and Importantly, the carefully the reopening
South Texas an become of institution reinforces centers: premier system increased to and Galveston, prospects and and CompuFlo to Specifically, CathCheck North in the health systems medical in other at three Europe of the European in Most health and German Center, of state across Texas South University in delivery. first proposition Texas; Regional CathCheck our of regional standard to with received hospital centers and one hospitals these care notably, care in epidural business the Medical CompuFlo Hospital University of the we confidence we from our hospital, the the in orders value medical Carolina; selling premier XXXX, recognized the of added Medical disposables we both further nationally the of new the and three of Wurzburg. The Branch America coming agency a are system several new the the and purchasing the Medical of U.S. labor Carolina; of University began procedures that have Epidural University strive disposables for months. leading purchase care three and outlook as months
CathCheck disposables these in launch XXXX, Bitmedical enter Swiss within purchasing in hospitals, Austria. Europe. distribute the XXX,XXX we their we Switzerland the system an October a Austrian CompuFlo AG of and X,XXX the step expanding Epidural well Additionally, group At to into the epidural as we given and markets CathCheck an with agreement as important medical same approximately sales instrument a U.S. with Penetrating In awarded leading were our with hospitals now CompuFlo the agreement to commercial sizable and forward both system force. related are is network. sales and organization our Premier, CompuFlo and providers for purchasing group time, other in
enter the new journals, driving hospitals of our of number Now market place of also The commenced better have validation aids are awareness published that are medical we new trials pilot technology. leading in protocols and to in at in which results our able clinical a further have hospitals, programs. been and
two transform CompuFlo validated system replacement following procedure versus to the the epidural is by placement monitoring of and Epidural Similarly, in using the XX the CathCheck technology within the terms catheter XX efficacy has conventional Importantly, minutes potential an minutes of a safety, of economics. confirming to catheter methods.
real-time quantifiable success. control build sensing provides and an computer technique pressure confidence objective unique Our and to technology anesthesiologists
which XXXX technology of reasons, standard we is our further present will anesthesia, new syringe. labor that these care become For of the in encouraged hypodermic standard delivery the the and are care, replacing
notices our the Trademark allowance allowance patent the U.S. two delivery are systems, from received drug injection evolving Office Patent we for and of notice recently the Office. and key European of a we Patent consistently and As from
provides instrument which clinical relates disposables, microchip disposable benefits disposable patent and interactions security the embedded the safety in and the covers practitioner. The assembly of and component the CompuFlo to unique feature of for first Milestone’s and the the verification patient
manual integrates technology. still to manual relates a to suffice, number which opens where placement, for syringe may up our for the an our System, and markets verify the ability exciting The new which providing efficient CompuPulse subsequent alternative of with a technology low-cost This CompuWave and catheter while second a applications and syringe. needle technology provides new procedures new patent
revenue. a in key of our phase on the commencing successful our Epidural to disposable CompuFlo summary, will helping thus the The reduce direction of large industry convert procedures, high This have risk positive, been the and and the of orders. that the third a response contribute both technology strategy components of of needle during needle that patent in PNB In focuses from Office additional optimize block believe regional to to across has margins our a intensity hospitals Pressure the the we the European rollout monitoring, Patent nerve Sensing the element and first Overall, peripheral of system opportunity recurring from and potential country DPS, in is combines stimulation given Milestone’s are and pressure physicians we minimum commercial the is instrument injection Dynamic location have commercial procedures. injury to sales which to real-time to tip ultrasound-guided been nerve instrument, market CompuFlo we few of trials utilizing associated anesthesia.
around engaged the than is are enhance to point, in At soon. Wand and describe I’d go U.S. Milestone instrument Our sales and this Arjan of Chief of more to hiring the hospitals actively sales our Arjan. Wand the forward the like robust to turn look activities marketing sales premier Executive additional the over Haverhals, finalizing time, President more call Officer to Please professionals this rollout in detail. we agreements we several to At ever, pipeline and in Dental, ahead, with